Pacific Biosciences of California, Inc. - Common Stock (PACB)
1.6800
-0.0600 (-3.45%)
NASDAQ· Last Trade: Jul 3rd, 12:48 PM EDT
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via StockStory · July 3, 2026
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...
Via StockStory · July 1, 2026
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofi...
Via StockStory · June 15, 2026
Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and i...
Via StockStory · June 1, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via StockStory · May 29, 2026
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying busi...
Via StockStory · May 18, 2026
What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) fell 14.2% in the afternoon session after the company reported mixe...
Via StockStory · May 8, 2026
PacBio (PACB) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 8, 2026
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year a...
Via StockStory · May 8, 2026
Pacific Biosciences of California (NASDAQ:PACB) reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument performance amid ongoing pressure in academic and government funding, particularly in the U.S.
Pres
Via MarketBeat · May 8, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via StockStory · May 8, 2026
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year a...
Via StockStory · May 7, 2026
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting earnings this Thursday after market hours. Here’s what investors should kn...
Via StockStory · May 5, 2026
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...
Via StockStory · April 29, 2026
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ...
Via StockStory · April 17, 2026
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via StockStory · March 27, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via StockStory · March 19, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and it...
Via StockStory · March 17, 2026
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...
Via StockStory · March 16, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via StockStory · March 13, 2026
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Via StockStory · March 6, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its ...
Via StockStory · March 3, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Via StockStory · March 1, 2026
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at the wholesale level, increased by 0.5% in January, significantly higher than the 0.3% anticipated by economists. More concerning was the core PPI, which excludes volatile food and energy prices, as it surged by 0.8%, far exceeding the expected 0.3% rise. This data suggests that inflation may be more entrenched than previously thought, potentially impacting future interest rate decisions. In response to the news, major market indices, including the S&P 500, Dow Jones, and Nasdaq, all traded sharply lower as investors reassessed the economic outlook.
Via StockStory · February 27, 2026
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings
Via MarketMinute · February 27, 2026